With Spark safely tucked into Roche, its founding CEO is off to search for new adventures
Spark Therapeutics made history at the FDA by winning the first-ever approval for a gene therapy, when the agency greenlighted Luxturna in late 2017. But the company and its founding CEO are preparing to turn a new leaf.
Jeff Marrazzo, Spark’s chief executive since its founding in 2013, will step down from his post on April 1, the biotech announced Wednesday morning. COO Ron Philip was tapped to succeed him after a transition period, and told Endpoints News he had planned to leave the company once its future with Roche was secure.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.